Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	15.12	25.66	18.59	39.65	27.14
Cash & Short-Term Investments	15.12	25.66	18.59	39.65	27.14
Cash Growth	-41.08%	38.02%	-53.11%	46.08%	-42.84%
Prepaid Expenses	1.03	2.04	1.95	2.17	2.32
Other Current Assets	1.11	0.01	0.01	0.01	0.01
Total Current Assets	17.25	27.71	20.55	41.82	29.47
Property, Plant & Equipment	0.02	0.05	0.09	-	-
Other Long-Term Assets	0.23	0.44	0.65	0.01	0.14
Total Assets	17.5	28.2	21.29	41.83	29.6
Accounts Payable	5.66	6.43	3.89	1.81	1.29
Accrued Expenses	8.19	9.14	9.02	7.16	4
Current Portion of Long-Term Debt	21.12	-	-	-	-
Current Portion of Leases	0.02	0.05	0.04	0.01	0.04
Other Current Liabilities	0.43	0.06	0.06	0.07	0.07
Total Current Liabilities	35.41	15.68	13.01	9.03	5.4
Long-Term Debt	85.11	71.74	39.83	29.05	-
Long-Term Leases	-	0.02	0.07	-	0.01
Other Long-Term Liabilities	0.05	1	0.57	1.13	-
Total Liabilities	120.57	88.44	53.48	39.21	5.41
Common Stock	0.06	0.06	0.06	0.06	0.06
Additional Paid-In Capital	296.22	291.85	275.08	271	261.88
Retained Earnings	-401.57	-354.37	-309.57	-270.69	-240
Total Common Equity	-105.29	-62.46	-34.43	0.37	21.94
Shareholders' Equity	-103.07	-60.24	-32.19	2.62	24.19
Total Liabilities & Equity	17.5	28.2	21.29	41.83	29.6
Total Debt	106.25	71.81	39.93	29.06	0.05
Net Cash (Debt)	-91.13	-46.15	-21.34	10.59	27.09
Net Cash Growth	-	-	-	-60.90%	-42.90%
Net Cash Per Share	-1.46	-0.77	-0.36	0.18	0.48
Filing Date Shares Outstanding	63.18	61.9	59.44	59.36	57.16
Total Common Shares Outstanding	63.16	61.85	59.43	59.34	57.08
Working Capital	-18.16	12.03	7.54	32.79	24.07
Book Value Per Share	-1.67	-1.01	-0.58	0.01	0.38
Tangible Book Value	-105.29	-62.46	-34.43	0.37	21.94
Tangible Book Value Per Share	-1.67	-1.01	-0.58	0.01	0.38
Machinery	0.07	0.07	0.07	0.07	0.07
Leasehold Improvements	0	0	0	0	0

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q